WO2016107118A1 - 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用 - Google Patents

一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用 Download PDF

Info

Publication number
WO2016107118A1
WO2016107118A1 PCT/CN2015/082408 CN2015082408W WO2016107118A1 WO 2016107118 A1 WO2016107118 A1 WO 2016107118A1 CN 2015082408 W CN2015082408 W CN 2015082408W WO 2016107118 A1 WO2016107118 A1 WO 2016107118A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
oligonucleic acid
modification
nucleic acid
positive
Prior art date
Application number
PCT/CN2015/082408
Other languages
English (en)
French (fr)
Inventor
王雪根
叶青
孙益军
Original Assignee
南京艾德凯腾生物医药有限责任公司
南京凯基生物科技发展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京艾德凯腾生物医药有限责任公司, 南京凯基生物科技发展有限公司 filed Critical 南京艾德凯腾生物医药有限责任公司
Priority to US15/538,288 priority Critical patent/US10441600B2/en
Publication of WO2016107118A1 publication Critical patent/WO2016107118A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Definitions

  • the invention belongs to the field of biomedicine, and particularly relates to an oligonucleic acid for preparing a medicament for inhibiting tumor growth and an application thereof.
  • Oligomeric nucleic acids can be divided into antisense nucleic acids, small interfering RNAs, aptamers, microRNAs, DECOY nucleic acids, etc., and their respective biological functions are exerted according to different target and mechanism. Oligomeric nucleic acids as therapeutic drugs have been approved for marketing in the United States, and dozens of varieties have been studied in clinical research. With the advancement of technologies such as biotechnology, drug screening and preparation, more and more specific functional oligomers have emerged. Nucleic acids have been discovered and developed and used to treat, prevent and diagnose various diseases.
  • the object of the present invention is to provide an oligonucleic acid for preparing a drug for inhibiting tumor growth and an application thereof, and to find a sequence 1 to a sequence 10 by screening a series of oligonucleic acid Oligo dsDNA and evaluating the antitumor activity.
  • the oligonucleic acid has an inhibitory effect on tumor growth in vitro and in vivo.
  • the present invention provides an oligonucleic acid for preparing a drug for inhibiting tumor growth, characterized in that the oligonucleic acid is any one of the following sequences 1 to 10:
  • the oligonucleic acid may also be the antisense strand of the above sequences 1 to 10.
  • the oligonucleic acid is a modified form of the oligonucleic acid described above.
  • the modification is a special site thiolation modification; or three nucleotides at each end of the thiolation Modification; or total thio modification.
  • the modified sites corresponding to the respective sequences are as follows:
  • the present invention also proposes the use of the above oligonucleic acid in the preparation of a medicament for inhibiting tumor growth.
  • the method comprises the following steps: the oligonucleic acid is purified by HPLC, and the sterilized water is formulated into a concentration of 1-2 mg/mL, and the oligonuclear is mixed with an antisense strand in an equimolar amount, and heated in a water bath. It is naturally cooled to room temperature at 80-85 ° C for 10 to 15 minutes, and annealed to form a double-strand for preparing a drug for inhibiting tumor growth.
  • the tumor is any one of lung cancer, breast cancer and pancreatic cancer.
  • the oligonucleic acid provided by the present invention has an inhibitory effect on tumor growth in vitro and in vivo, and is expected to be used for preparing a drug for inhibiting tumor growth, which has high specificity and high inhibition rate.
  • Figure 1 is a schematic diagram showing the change of growth volume of human breast cancer cell MDA-MB-231 xenograft tumor in nude mice by sequence 5 (KT17);
  • FIG. 2 is a schematic diagram showing the inhibitory effect of sequence 5 (KT17) on human breast cancer cell MDA-MB-231 xenograft tumor growth in nude mice;
  • Figure 3 is a photograph showing the change in growth volume of human breast cancer cell MDA-MB-231 xenograft tumor in nude mice by sequence 5 (KT17);
  • Figure 4 is a schematic diagram showing the change of growth volume of human pancreatic cancer cell line CFPAC-1 xenograft tumor in nude mice by nucleic acid sequence 8 (KT59);
  • Figure 5 is a graphical representation of the inhibition of nucleic acid sequence 1 (KT32) on human lung cancer cell NCI-H1975 xenograft tumor growth in nude mice.
  • oligonucleic acids provided by the present invention are mainly divided into three categories, for a total of 10 sequences, as follows:
  • Oligo dsDNA consisting mainly of the core sequence RGGGAHTTYCS includes:
  • Oligo dsDNA consisting mainly of the core sequence TTYSGGAAWT, including:
  • Oligo dsDNA consisting mainly of the core sequence TTTCSCGCS, including:
  • Example 1 Inhibition of tumor cell growth by oligonucleic acids in vitro.
  • the synthesized oligonucleic acids of Sequence 1 to Sequence 10 and their antisense strands are simultaneously modified by different structures, including three, specific sites of thio (as described above), three bases at both ends, and all The thio-three groups were purified by HPLC and the purity was over 90%. After the sterilized water was prepared to a concentration of 1 mg/mL, the anti-sense strands were mixed in equimolar number, heated in a water bath to 85 ° C for 10 minutes, naturally cooled to room temperature, and annealed. Double-chain alternate.
  • the breast cancer cell line MDA-MB-231, the lung cancer cell line NCI-H1975, and the pancreatic cancer cell line CFPAC-1 were cultured in vitro according to conventional methods. When the cells were grown to 10 5 -10 6 /mL, the cells were digested and counted.
  • Example 2 Inhibition of oligonucleic acid on growth of human xenograft tumors in animals.
  • the nucleic acid samples of Sequence 1, Sequence 5, and Sequence 8 were separately formulated into cationic liposome preparations, the control drug was selected from paclitaxel (positive control group), the physiological saline control group (negative control group), and low. There were 5 groups in the middle, high and high dose groups.
  • the test animals were 12-15 g, female BALB/c nude mice of 4 to 5 weeks, and the like. The cultured tumor cell suspension was collected and inoculated subcutaneously into the right axilla of nude mice. After 7 to 9 days of inoculation, the animals were randomly divided into groups of 8 animals each growing to 50-75 mm 3 .
  • each group of nude mice began to be administered, the number of administrations was 1 time/day, 14-18 days, and the administration method was tail vein injection.
  • the method of measuring the tumor diameter was used to dynamically observe the anti-tumor effect of the test sample.
  • the nude mice were sacrificed 14-18 days after the administration, and the tumor pieces were surgically removed and weighed and photographed.
  • the formula for calculating tumor volume (TV) is:
  • V0 is the measured tumor volume at the time of sub-cage administration (ie, d0)
  • Vt is the tumor volume at each measurement.
  • Evaluation index of anti-tumor activity relative tumor growth rate T/C (%), the calculation formula is as follows:
  • the mean value was expressed by X ⁇ SD, and the inter-group analysis was statistically processed by t-test.
  • the results were statistically analyzed using SPSS (Staffstical Package for the Social Science) 17.0.
  • sequence provided by the present invention has a significant inhibitory effect on tumor growth and can be further developed as a drug candidate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供了用于制备抑制肿瘤生长药物的寡聚核酸及其应用，该寡聚核酸的核心序列为TTTCSCGCS，其中，S为C或G。该寡聚核酸还包括其反义链和修饰型。

Description

一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用 技术领域
本发明属于生物医药领域，具体涉及一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用。
背景技术
寡聚核酸可分为反义核酸、小干扰RNA、适配体、微小RNA、DECOY核酸等，按作用靶点与机制的不同，发挥其各自生物学功能。作为治疗药物的寡聚核酸已在美国获批上市，同时进行临床研究的也有数十个品种，随着生物技术、药物筛选与制备等技术的进步，越来越多的有特定功能的寡聚核酸被发现，并被开发和应用于治疗、预防和诊断各种疾病。
发明内容
发明目的：本发明的目的在于提供一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用，通过对系列寡聚核酸Oligo dsDNA的筛选和抑癌活性评价试验，发现了序列1～序列10的寡聚核酸对体内外肿瘤生长有抑制作用。
技术方案：为实现上述技术目的，本发明提供一种用于制备抑制肿瘤生长药物的寡聚核酸，其特征在于，所述寡聚核酸为下述序列1～10中的任意一种：
序列1：5`-CTTGAGGGGAATTTCCCAG-3`
序列2：5`-GAGAGGGGACTTTCCGAGAG-3’
序列3：5`-CCTTGAAGGGATTTCCCTCC-3`
序列4：5’-GCCATTTCCGGGAATTGCTA-3’
序列5：5’-AGTTCTGGGAATTCC-3’
序列6：5’-AGTCATTTCCGGGAAATGACT-3’
序列7：5’-TGACTATTTCCCGCGACTT-3’
序列8：5’-TTGACTATTTCCCGCCACTT-3’
序列9：5’-ATCTATTTCGCGCCCTTATG-3’
序列10：5’-TTAAGTTTCGCGCCCTTTCTC-3’。
所述的寡聚核酸还可以为上述序列1～10的反义链。
作为另一种实施方案，所述的寡聚核酸为上述的寡聚核酸的修饰型。
具体地，所述的修饰型为特别位点硫代化修饰；或两端各3个核苷酸硫代化 修饰；或全硫代修饰。
优选地，对应各个序列的修饰的位点如下：
序列1(正)：5’-CTTGAGGGGAATTTCCCAG-3’
序列2(正)：5’-GAGAGGGGACTTTCCGAGAG-3’
序列3(正)：5’-CCTTGAAGGGATTTCCCTCC-3’
序列4(正)：5’-GCCATTTCCGGGAATTGCTA-3’
序列5(正)：5’-AGTTCTGGGAATTCC-3’
序列6(正)：5’-AGTCATTTCCGGGAAATGACT-3’
序列7(正)：5’-TGACTATTTCCCGCGACTT-3’
序列8(正)：5’-TTGACTATTTCCCGCCACTT-3’
序列9(正)：5’-ATCTATTTCGCGCCCTTATG-3’
序列10(正)：5’-TTAAGTTTCGCGCCCTTTCTC-3’
其中，正表示即仅列出正义链，反义链略。
本发明同时提出了上述寡聚核酸在制备用于抑制肿瘤生长的药物中的应用。
具体地，包括如下步骤：将所述的寡聚核酸经HPLC纯化，灭菌水配制成浓度1～2mg/mL后，将该寡聚核素与其反义链进行等摩尔数混合、水浴加温至80～85℃10～15分钟，自然冷却至室温，退火结合成双链用于制备抑制肿瘤生长的药物。
其中，所述的肿瘤为肺癌、乳腺癌和胰腺癌中的任意一种。
有益效果：本发明提供的寡聚核酸对体内外肿瘤生长有抑制作用，有望用于制备抑制肿瘤生长的药物，专一性高，抑制率高。
附图说明
图1为序列5(KT17)对人乳腺癌细胞MDA-MB-231裸鼠异种移植肿瘤生长体积变化的示意图；
图2为序列5(KT17)对人乳腺癌细胞MDA-MB-231裸鼠异种移植肿瘤生长的抑制作用的示意图；
图3为为序列5(KT17)对人乳腺癌细胞MDA-MB-231裸鼠异种移植肿瘤生长体积变化的照片；
图4为核酸序列8(KT59)对人胰腺癌细胞CFPAC-1裸鼠异种移植肿瘤生长体积变化的示意图；
图5为核酸序列1(KT32)对人肺癌细胞NCI-H1975裸鼠异种移植肿瘤生长的抑制作用的示意图。
具体实施方式
本发明提供的寡聚核酸主要分三类，共计10个序列，具体如下:
第一类:主要由核心序列RGGGAHTTYCS所组成的Oligo dsDNA包括:
序列1(正)：5’-CTTGAGGGGAATTTCCCAG-3’
序列2(正)：5’-GAGAGGGGACTTTCCGAGAG-3’
序列3(正)：5’-CCTTGAAGGGATTTCCCTCC-3’
第二类:主要由核心序列TTYSGGAAWT所组成的Oligo dsDNA，包括:
序列4(正)：5’-GCCATTTCCGGGAATTGCTA-3’
序列5(正)：5’-AGTTCTGGGAATTCC-3’
序列6(正)：5’-AGTCATTTCCGGGAAATGACT-3’
第三类:主要由核心序列TTTCSCGCS所组成的Oligo dsDNA,包括:
序列7(正)：5’-TGACTATTTCCCGCGACTT-3’
序列8(正)：5’-TTGACTATTTCCCGCCACTT-3’
序列9(正)：5’-ATCTATTTCGCGCCCTTATG-3’
序列10(正)：5’-TTAAGTTTCGCGCCCTTTCTC-3’
其中，正即仅列出正义链，反义链略；修饰类型中，一类为部位位点硫代化修饰，下划线处为修饰位点，另一类为两端各3个核苷酸硫代化修饰或全硫代修饰，R＝G/A；H＝A/C/T；Y＝C/T；S＝C/G；W＝A/T。
下面通过具体的实施例说明上述寡聚核酸对肿瘤的抑制作用。
实施例1 寡聚核酸体外对肿瘤细胞生长的抑制作用。
合成的序列1～序列10及其反义链的寡聚核酸，同时经过不同的结构修饰，包括三种，特定位点的硫代(如上所述)、两端3个碱基硫代和全硫代三组，经HPLC纯化，纯度90％以上，灭菌水配制成浓度1mg/mL后，正反义链等摩尔数混合、水浴加温至85℃10分钟，自然冷却至室温，退火结合成双链备用。
体外按常规方法分别培养乳腺癌细胞株MDA-MB-231、肺癌细胞株NCI-H1975、胰腺癌细胞株CFPAC-1，待细胞生长到105-106个/mL时，细胞消化收集、计数、配制成浓度为3～5×104个/mL的细胞悬液，于96孔细胞培养板中每孔加入100μL细胞悬液(每孔3～5×103个细胞)；将96孔细胞培养板置于 37℃，5％CO2培养箱中培养24小时；用完全培养基稀释各组寡聚核酸至所需浓度，每孔加入100μL相应的含寡聚核酸的培养基，同时设立阴性对照组和阳性对照组，其中，阴性对照组为生理盐水，阳性对照组为紫杉醇，转染方法参照Lipofectimine的产品说明书；96孔细胞培养板置于37℃，5％CO2培养箱中培养72小时；每孔加入20μL MTT(5mg/mL)，在培养箱继续培养4小时；弃去培养基，每孔加入150μL DMSO溶解，摇床10分钟轻轻地混匀；酶标仪λ＝490nm读取每孔的OD值，计算抑制率。
各组抑制率的计算方法：
Figure PCTCN2015082408-appb-000001
体外筛选结果表明，序列1～10的三类修饰组均对肿瘤细胞生长有一定的抑制作用，其中序列1～10的特定位点硫代代修饰组(硫代位点见序列表有下划线处)在体外对不同肿瘤细胞有较好的生长抑制作用。其试验结果如表1所示：
表1
Figure PCTCN2015082408-appb-000002
部份复筛实验结果如表2和表3所示：
表2
Figure PCTCN2015082408-appb-000003
表3
Figure PCTCN2015082408-appb-000004
实施例2 寡聚核酸在动物体对人异植肿瘤生长的抑制作用。
将序列1、序列5、序列8的核酸样品(特定位点修饰组)分别配制成阳离子脂 质体制剂，对照药物选用紫杉醇(阳性对照组)，生理盐水对照组(阴性对照组)、、低、中、高剂量组共5组。受试动物为12～15g，4～5周的雌性BALB/c裸小鼠等。收集培养的肿瘤细胞悬液，接种于裸小鼠右侧腋窝皮下，接种7～9天后，肿瘤生长至50～75mm3时将动物随机分组，每组8只。同时，各组裸鼠开始给药，给药次数1次/日，14-18天，给药方式为尾静脉注射，使用测量瘤径的方法，动态观察受试样品的抗肿瘤效应。给药14-18天后随即处死裸鼠，手术剥取瘤块称重，拍照。
肿瘤体积(tumor volume,TV)的计算公式为：
TV＝1/2×a×b2
其中a、b分别表示长宽。
根据测量的结果计算出相对肿瘤体积(relative tumor volume，RTV)，计算公式为：
RTV＝Vt/V0,
其中V0为分笼给药时(即d0)测量所得肿瘤体积，Vt为每一次测量时的肿瘤体积。
抗肿瘤活性的评价指标：相对肿瘤增殖率T/C(％)，计算公式如下：
Figure PCTCN2015082408-appb-000005
TRTV：治疗组RTV；CRTV：模型组RTV
均值用X±SD表示，组间分析用t检验进行统计学处理，应用SPSS(Staffstical Package for the Social Science)17.0对结果进行统计分析。
上述体内药效试验结果表明，核酸序列5(KT17)对乳腺癌细胞MDA-MB-231的体内抑制率高中低剂量组分别达到：47.13％、66.42％和41.81％。(如图1～3所示)核酸序列8(KT59)对胰腺癌CFPAC-1的体内抑制率高中低剂量组分别达到：64.36％、57.89％和44.15％，抑瘤率较高并有一定的量效关系。(如图4所示)核酸序列1(KT32)对肺癌细胞NCI-H1975的体内抑制率高、低剂量组分别达到：56.35％和49.44％(如图5所示)。
综上所述，本发明提供的序列对肿瘤生长有明显抑制作用，可作为候选药物进一步开发。
Figure PCTCN2015082408-appb-000006
Figure PCTCN2015082408-appb-000007
Figure PCTCN2015082408-appb-000008

Claims (7)

  1. 一种用于制备抑制肿瘤生长药物的寡聚核酸，其特征在于，所述寡聚核酸为下述序列中的任意一种：
    5’-TGACTATTTCCCGCGACTT-3’；
    5’-TTGACTATTTCCCGCCACTT-3’；
    5’-ATCTATTTCGCGCCCTTATG-3’；
    5’-TTAAGTTTCGCGCCCTTTCTC-3’。
  2. 根据权利要求1所述的寡聚核酸，其特征在于，所述的寡聚核酸为权利要求1中的序列的反义链。
  3. 根据权利要求1或2所述的寡聚核酸，其特征在于，所述的寡聚核酸为权利要求1或2所述的寡聚核酸的修饰型。
  4. 根据权利要求3所述的寡聚核酸，其特征在于，所述的修饰型为特别位点硫代化修饰；或两端各3个核苷酸硫代化修饰；或全硫代修饰。
  5. 权利要求1～4任一项所述的寡聚核酸在制备用于抑制肿瘤生长的药物中的应用。
  6. 根据权利要求5所述的应用，其特征在于，包括如下步骤：将所述的寡聚核酸经HPLC纯化，灭菌水配制成浓度1～2mg/mL后，将该寡聚核素与其反义链进行等摩尔数混合、水浴加温至80～85℃10～15分钟，自然冷却至室温，退火结合成双链用于制备抑制肿瘤生长的药物。
  7. 根据权利要求5所述的应用，其特征在于，所述的肿瘤为肺癌、乳腺癌和胰腺癌中的任意一种。
PCT/CN2015/082408 2014-12-30 2015-06-25 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用 WO2016107118A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/538,288 US10441600B2 (en) 2014-12-30 2015-06-25 Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410844012.2 2014-12-30
CN201410844012.2A CN105255862B (zh) 2014-12-30 2014-12-30 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用

Publications (1)

Publication Number Publication Date
WO2016107118A1 true WO2016107118A1 (zh) 2016-07-07

Family

ID=55095792

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CN2015/082397 WO2016107115A1 (zh) 2014-12-30 2015-06-25 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用
PCT/CN2015/082403 WO2016107117A1 (zh) 2014-12-30 2015-06-25 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用
PCT/CN2015/082408 WO2016107118A1 (zh) 2014-12-30 2015-06-25 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/CN2015/082397 WO2016107115A1 (zh) 2014-12-30 2015-06-25 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用
PCT/CN2015/082403 WO2016107117A1 (zh) 2014-12-30 2015-06-25 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用

Country Status (3)

Country Link
US (3) US10251907B2 (zh)
CN (1) CN105255862B (zh)
WO (3) WO2016107115A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1507874A (zh) * 2002-03-28 2004-06-30 青 叶 肿瘤基因开关药物
CN1507875A (zh) * 2002-03-28 2004-06-30 青 叶 肿瘤基因开关药物
CN1507873A (zh) * 2002-03-28 2004-06-30 青 叶 肿瘤基因开关药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7781400A (en) * 1999-09-24 2001-04-24 Consejo Superior De Investigaciones Cientificas Wheat dp proteins and uses thereof
CN1240439C (zh) * 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
CN1665929A (zh) * 2002-04-26 2005-09-07 安琪士多摩奇株式会社 含有转录dna结合位点的环状哑铃状诱饵寡脱氧核苷酸(cdodn)
US20060241066A1 (en) * 2002-05-29 2006-10-26 Tetsuya Tomita Decoy composition for treating and preventing inflammatory disease
CN1506117A (zh) * 2002-12-11 2004-06-23 南京凯基生物科技发展有限公司 抗肿瘤的基因转录调控药物
EP1671655A4 (en) * 2003-08-29 2009-08-12 Anges Mg Inc GENE THERAPY FOR SKIN DISEASE USING NEEDLE-FREE SYRINGE
US7323308B2 (en) * 2004-09-03 2008-01-29 Affymetrix, Inc. Methods of genetic analysis of E. coli
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
EP1892293A4 (en) * 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
WO2011130658A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Custom designed microbubble contrast agents and techniques of ultrasound delivery optimized for nucleic acid delivery to alter gene expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1507874A (zh) * 2002-03-28 2004-06-30 青 叶 肿瘤基因开关药物
CN1507875A (zh) * 2002-03-28 2004-06-30 青 叶 肿瘤基因开关药物
CN1507873A (zh) * 2002-03-28 2004-06-30 青 叶 肿瘤基因开关药物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, XUEGEN ET AL.: "Antitumor Activity of Decoy Oligonucleotides Targeted to AP -1 in Vitro and in Vivo", PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, vol. 31, no. 1, 31 December 2004 (2004-12-31), pages 27 - 31, ISSN: 1000-3282 *

Also Published As

Publication number Publication date
US10525077B2 (en) 2020-01-07
US10251907B2 (en) 2019-04-09
US20180135047A1 (en) 2018-05-17
CN105255862A (zh) 2016-01-20
US20180140627A1 (en) 2018-05-24
WO2016107115A1 (zh) 2016-07-07
US10441600B2 (en) 2019-10-15
WO2016107117A1 (zh) 2016-07-07
US20180142238A1 (en) 2018-05-24
CN105255862B (zh) 2018-05-22

Similar Documents

Publication Publication Date Title
JP2022532169A (ja) オリゴヌクレオチド組成物及びその使用方法
JP2017513869A (ja) 抗腫瘍における環状ジヌクレオチドｃＧＡＭＰの応用
JP2019526624A (ja) 細胞透過性が向上したペプチド核酸複合体およびそれを含む薬学的組成物
CN109475644A (zh) 利用铂金类抗癌剂诱导的细胞内增加的p53水平的维持方法及其运用
JP2011527291A5 (zh)
US20230056466A1 (en) Novel precursor mirna and application thereof in tumor treatment
JP7478720B2 (ja) 条件付き再プログラム化細胞から動物モデルを得るための方法および抗腫瘍薬のスクリーニングのための動物モデルの使用
CN102719432B (zh) 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
CN102548986A (zh) 氨基吡咯烷酮衍生物及其用途
CN107531768A (zh) 抗衰老化合物及其用途
Liu et al. MircoRNA-29a in astrocyte-derived extracellular vesicles suppresses brain ischemia reperfusion injury via TP53INP1 and the NF-κB/NLRP3 axis
US10351856B2 (en) Ribonucleic acid aptamer having inhibitory effect on non-small cell lung cancer and pharmaceutical composition comprising same
CN102784398B (zh) 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用
CN116785445A (zh) 靶向化学药物及其制备方法、药物组合物、靶向化学药物的应用
US20130303611A1 (en) Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis
WO2016107115A1 (zh) 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用
CN106999573A (zh) 佐剂组合物
WO2017065563A1 (ko) Rna 올리고뉴클레오티드를 포함하는 암 치료용 약학 조성물
US11352392B2 (en) Artificially synthesized peptide H-473 and use thereof
US11207425B2 (en) Guide RNA molecule and method for treating cancer
CN107709561A (zh) 修饰的siRNA及含有该修饰的siRNA的药物组合物
JP6630824B2 (ja) Ｒｎａオリゴヌクレオチドを含むがん治療用医薬組成物
KR20150110385A (ko) 강심 배당체를 이용한 stk11-돌연변이 암 치료용 약학적 조성물
CN111094324A (zh) 一种溶瘤病毒、合成dna序列及其应用
US11857584B2 (en) Oncolytic virus growth method and antitumor agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15874808

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15538288

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15874808

Country of ref document: EP

Kind code of ref document: A1